Curated News
By: NewsRamp Editorial Staff
July 02, 2025
Transdermal Patch Market Booms with Innovations in Pain Therapy
TLDR
- Nutriband Inc. offers investors early exposure to the growing transdermal patch market with its AVERSA Fentanyl, a potential leader in abuse-deterrent opioid pain management.
- The transdermal patch market, valued at $7.8 billion in 2023, is projected to reach $10.95 billion by 2030, with pain patches leading the growth.
- Transdermal drug delivery offers a safer alternative to traditional opioids, addressing chronic pain and reducing needle use, making healthcare more accessible and safer.
- Discover how small-cap biopharma companies like Nutriband are innovating in pain therapy with transdermal patches, combining technology and healthcare for safer drug delivery.
Impact - Why it Matters
The advancements in transdermal patch technology and the growth of the abuse-deterrent opioid segment represent a significant shift in drug delivery methods, offering safer alternatives for pain management and reducing the risk of opioid abuse. This development is crucial for patients seeking effective and less invasive treatment options, as well as for investors looking for opportunities in the biopharma sector. The focus on innovative solutions by companies like Nutriband, Collegium Pharmaceutical, Assertio Holdings, and Aquestive Therapeutics highlights the potential for transformative changes in healthcare and pain therapy.
Summary
The global transdermal patch market is on a significant growth trajectory, with a valuation of $7.8 billion in 2023 and projections to reach nearly $10.95 billion by 2030. Pain patches are at the forefront of this expansion, expected to grow from $4.8 billion in 2021 to $7.3 billion by 2031. This growth is not only due to the convenience of transdermal drug delivery but also its ability to address critical healthcare challenges, such as managing chronic pain in aging populations and providing a safer alternative to traditional opioid use. The abuse-deterrent opioid segment is particularly noteworthy, with projections to more than double between 2024 and 2030, attracting investor interest.
Key players in this market include Nutriband Inc. (NASDAQ: NTRB), Collegium Pharmaceutical, Inc. (Nasdaq: COLL), Assertio Holdings, Inc. (Nasdaq: ASRT), and Aquestive Therapeutics, Inc. (Nasdaq: AQST). Nutriband is making waves with its AVERSA Fentanyl patch, designed to deter abuse, misuse, and accidental exposure, potentially reaching peak annual US sales of between 80 million and 200 million dollars. Collegium Pharmaceutical is seeing consistent revenue growth, with its ADHD medication Jornay PM and chronic pain medications like Belbuca and Xtampza ER driving performance. Assertio Holdings is streamlining operations and focusing on high-potential assets, while Aquestive Therapeutics is advancing innovative delivery technologies for complex molecules, including a promising oral sublingual film for severe allergic reactions.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Transdermal Patch Market Booms with Innovations in Pain Therapy
